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ABSTRACT
Background Severe asthma is a heterogeneous
condition. Airway remodelling is a feature of severe
asthma and can be determined by the assessment of
high-resolution computed tomography (HRCT) scans. The
aim of this study was to assess whether airway
remodelling is restricted to speciﬁc subphenotypes of
severe asthma.
Methods A retrospective analysis was performed of
HRCT scans from subjects who had attended a single-
centre severe asthma clinic between 2003 and 2008.
The right upper lobe apical segmental bronchus (RB1)
dimensions were measured and the clinical and sputum
inﬂammatory characteristics associated with RB1
geometry were assessed by univariate and multivariate
regression analyses. Longitudinal sputum data were
available and were described as area under the time
curve (AUC). Comparisons were made in RB1 geometry
across subjects in four subphenotypes determined by
cluster analysis, smokers and non-smokers, and subjects
with and without persistent airﬂow obstruction.
Results Ninety-nine subjects with severe asthma and
16 healthy controls were recruited. In the subjects with
severe asthma the RB1 percentage wall area (%WA)
was increased (p¼0.009) and lumen area (LA)/body
surface area (BSA) was decreased (p¼0.008) compared
with controls but was not different across the four
subphenotypes. Airway geometry was not different
between smokers and non-smokers and RB1 %WA was
increased in those with persistent airﬂow obstruction.
RB1 %WA in severe asthma was best associated with
airﬂow limitation and persistent neutrophilic airway
inﬂammation (model R
2¼0.27, p¼0.001).
Conclusions Airway remodelling of proximal airways
occurs in severe asthma and is associated with impaired
lung function and neutrophilic airway inﬂammation.
INTRODUCTION
Asthma,a common complexinﬂammatorydisorder,
affects about 5% of adults in the general population,
of which approximately 5e10% suffer from severe
asthma.
1 This severe asthma group is important as
these patients suffer severe morbidity and consume
a disproportionately high amount of healthcare
resources.
2 Airway remodelling, characterised by
changes such as increase in airway smooth muscle
mass due to hyperplastic and hypertrophic changes,
mucous gland hyperplasia, thickening of reticular
basement membrane, dysregulated extracellular
matrix deposition and increased vasculature, is
important and considered fundamental to the chro-
nicity of the asthma disease complex.
3
Airway wall changes in severe asthma are
common and impossible to predict without
imaging.
4 High-resolution computed tomography
(HRCT) has emerged as a repeatable and accurate
tool for non-invasive quantitative assessment of
proximal airway structural changes in patients
with asthma.
5e8 Thickening of the right upper lobe
apical segmental bronchus (RB1) has been shown
to correlate with airﬂow limitation,
6 airway hyper-
responsiveness
8 and air trapping on expiratory CT
scans
9 in asthma. Remodelling of RB1 has also been
shown to correlate well with non-RB1 proximal
airways in severe asthma.
68
The heterogeneity of asthma is highlighted by
different phenotypes identiﬁed using cluster anal-
ysis.
10 Dividing a multidimensional disease
complex such as asthma into distinct phenotypes
may help target treatment more effectively, as
exempliﬁed by the success of eosinophilic airway
inﬂammation-directed corticosteroid and anti-
interleukin 5 (IL-5) treatment
71 11 2to prevent
asthma exacerbations. A critical gap in improving
our understanding of severe asthma phenotypes is
identiﬁcation of remodelling patterns in various
subtypes of severe asthma and the ability to relate
airway structure to important clinical outcomes.
We hypothesised that airway remodelling
assessed by CT is different between severe asthma
subphenotypes. Our study aims were (1) to
compare CT-derived dimensions of RB1 between
severe asthma subphenotypes determined by
cluster analysis and (2) to identify clinical features
relating to patients’ demographic proﬁles, symp-
toms, pulmonary functions or airway inﬂamma-
tion that are best associated with the geometry of
RB1.
METHODS
Subjects
We performed a single-centre retrospective cross-
sectional study based on the ‘difﬁcult asthma’ clinic
at Glenﬁeld Hospital, Leicester, UK. Of 364 patients
attending the clinic between April 2003 and April
2008, 173 had HRCTscans and were considered for
inclusion in the study. The clinical indications for
HRCT scanning were determined by the attending
physician as described previously.
4 Pregnant and
lactating women were not subjected to CT scan-
ning. Subjects attending the clinic undergo an
extensive re-evaluation as part of their routine
clinical care, including an extensive history, skin
prick tests for common aeroallergens, spirometry,
methacholine challenge tests, sputum induction
13
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Asthmaand asthma control questionnaire.
14 The diagnosis of asthma is
conﬁrmed by a respiratory physician based on history and one or
more of the following objective criteria: maximum diurnal peak
expiratory ﬂow variability >20% over a 2-week period, signiﬁ-
cant bronchodilator reversibility deﬁned as an increase in forced
expiratory volume in 1 s (FEV1) >200 ml post-bronchodilator or
a concentration of methacholine provoking a fall in FEV1 of
<8 mg/ml. Severe asthma was deﬁned in accordance with the
American Thoracic Society workshop on refractory asthma.
15
The non-asthmatic controls were referred to our centre with
symptoms that were transient and resolved spontaneously on
follow-up. They were all non-smokers (never or ex-smokers with
a smoking history <10 pack-years) and had normal spirometry
and CT scans.
Informed consent for clinical characterisation and CT scan-
ning was obtained from all subjects and the study was approved
by the Leicestershire, Northamptonshire and Rutland research
ethics committee.
Cross-sectional imaging
HRCT was performed using a Siemens Sensation 16 scanner.
Scans were acquired using a standard HRCT protocol (sequen-
tial scanning at 10 mm increments with 1 mm collimation)
from the apex of the lung to the diaphragm. Patients were
scanned in the supine position at maximal inspiration (adequate
breath holding rehearsed prior to scan) with their arms held over
their heads. Images were reconstructed using a high spatial
frequency algorithm through a 5123512 matrix with a small
ﬁeld of view targeted to image only pulmonary areas. Scanning
time ranged from 30 s to 45 s with a voltage of 120 kVp and
peak effective tube current (dose modulation based on size and
attenuation proﬁle of the region scanned used to minimise
radiation dose) of 140 mAs (range 65e140). Long-acting bron-
chodilator therapy was not withheld prior to the HRCT scan.
Quantitative airway analysis
An automated program Emphylyx-J V 1.00.01
16 using the full
width at half-maximum (FWHM) technique was used to
determine the airway cross-sectional geometry. Image data were
transferred from the CTworkstation to a personal computer in
DICOM 3.0 format. After identifying the RB1, the operator
placed a seed point in the airway lumen from which 64e128
rays were cast across the airway wall. The boundaries of the
wall were deﬁned by the mid point of the proﬁle of CT numbers
across each ray. Lumen area (LA), wall area (WA) and maximum
and minimum airway diameter were measured. A high spatial
frequency algorithm was used for reconstruction of images as it
results in reduced blurring and, as shown by phantom studies,
17
is associated with reduced errors in airway wall estimation using
the FWHM method.
We used a previously reported airway phantom, modelling the
RB1 which had been validated against stereomicroscopy and
Micro-CT as gold standards for cross-sectional geometry.
8
Correction equations for both size-dependent error using the
FWHM method and oblique orientation of the airways were
applied as previously described.
7 LA and WA were corrected for
body surface area (BSA). Total area (TA) and percentage WA (%
WA) were derived from LA and WA (TA¼LA+WA; %WA¼WA/
TA3100).
The following aspects of the analysis are described in the
online supplement: (1) interobserver variability for airway
dimensions; (2) assessment of variability in measurement of RB1
across its length; and (3) assessment of the right B10 bronchus
(RB10) to further validate ﬁndings from RB1.
Data analysis
Data analysis was performed in three steps. First, a priori anal-
ysis was performed in patients with severe asthma dichotomised
into clinically relevant groups based on (1) the presence or
absence of chronic persistent airﬂow obstruction (FEV1 <70% of
predicted value and FEV1/forced vital capacity (FVC) <70%)
18;
(2) smoking history (smokers deﬁned as subjects with $10 pack-
years smoking history); (3) gender; and (4) eosinophilic airway
inﬂammation (non-eosinophilic severe asthma (NEA) was
deﬁned as subjects with asthma who had a sputum eosinophil
count of #1.9%
19 on at least two occasions with no previous
evidence of signiﬁcant eosinophilia >1.9%, eosinophilic asthma
(EA) was deﬁned as subjects with asthma and a sputum eosin-
ophil count of $3%
11 on at least two occasions; 30 and 16
patients qualiﬁed as EA and NEA, respectively). Unbiased
phenotyping of subjects with severe asthma was then under-
taken using factor and cluster analysis techniques as described
previously.
10 Brieﬂy, a two-step cluster analysis methodology
was employed using representative variables identiﬁed on factor
analysis.
10 The number of likely clusters was estimated using
hierarchical cluster analysis. This estimate was prespeciﬁed in
a k-means cluster analysis that was used as the principal clus-
tering technique. Finally, univariate and multiple regression
analysis was performed to explore the structure and function
relationship in severe asthma.
Statistical analysis
Statistical analysis was performed using GraphPad Prism Version
5.00 for Windows (GraphPad Software, San Diego, California
USA) and standard multiple regression using SPSS for Windows
Release 16.0.1.2008 (SPSS Inc, Chicago, Illinois, USA). Para-
metric data were expressed as mean (SEM) and non-parametric
data were described as median (interquartile range, IQR). c
2
tests were used for categorical data analysis. The unpaired t test
was used to compare clinical characteristics and RB1 dimensions
of dichotomised subjects with severe asthma and the Mann-
Whitney U test was used to compare sputum characteristics of
the dichotomised severe asthma groups. One-way analysis of
variance with Tukey correction (clinical characteristics and RB1
dimensions) and Kruskal-Wallis test with Dunn’s intergroup
comparison (sputum characteristics) was used to compare severe
asthma subphenotypes determined by cluster analysis. One-way
analysis of variance with Tukey correction was used to assess the
effect of varying tube currentetime product (mAs) on airway
phantom dimensions. Two-way analysis of variance was used to
assess variability in the dimension of RB1 across its length at
three levels and between subjects.
Pearson correlation coefﬁcient was used to determine the
relationship between RB1 dimensions (LA/BSA, WA/BSA, TA/
BSA and %WA) and clinical indices. The relationship between
RB1 %WA and clinical indices was further explored using stan-
dard multiple regression. A p value of <0.05 was taken as
statistically signiﬁcant.
RESULTS
Patients with severe asthma, measurable RB1 and sufﬁcient
baseline data to perform cluster analysis as described previ-
ously
10 (n¼99) were included in the study. Seventy-three of the
patients included in this study had also participated in
a previous study.
4 Longitudinal sputum data obtained at
scheduled clinic visits were available for 91% of subjects (>2
sputum samples over period of at least 3 months; median (IQR)
number of samples 5 (3e9) and duration 22 (11e38) months)
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Asthmaand were described as area under the time curve expressed as the
differential cell count/unit of time (AUC%).
Patients with severe asthma dichotomised into clinically
relevant groups
In the severe asthma group as a whole we found that mean
(SEM) RB1 %WA was signiﬁcantly greater in subjects with
persistent airﬂow obstruction than in those without (73.8 (1.5)
vs 69.0 (0.7), p¼0.006). There was no signiﬁcant difference in
RB1 %WA between smokers and non-smokers (71.9 (1.5) vs 69.7
(0.8), p¼0.2). Women had a greater RB1 LA/BSA (mm
2/m
2) (5.8
(0.4) vs 4.8 (0.3), p¼0.05) and RB1 WA/BSA (mm
2/m
2) (13.0
(0.6) vs 11.2 (0.5), p¼0.03) than men, but no signiﬁcant differ-
ence was found in RB1 %WA. There was no difference in RB1 %
WA between patients with EA (n¼30) and those with NEA
(n¼16) (70.5 (1.2)% vs 70.6 (1.3)%, p¼0.2). Further details are
shown in tables S2, S3, S4 and S5 in the online supplement.
Unbiased phenotyping of subjects with severe asthma using
cluster analysis
The clinical characteristics of the four severe asthma subphe-
notypes (groups AeD) determined by cluster analysis and
controls are shown in table 1. No signiﬁcant differences were
found between groups with regard to age. The severe asthma
subphenotypes were similar with regard to FEV1% predicted,
FEV1/FVC ratio and treatment with long-acting b agonists and
inhaled or oral corticosteroids. Group A represents patients with
severe asthma with a concordant asthma control score and
eosinophilic inﬂammation with a signiﬁcantly greater broncho-
dilator response. Group B consisted of patients with severe
asthma who were predominantly women with high body mass
index and evidence of a high asthma control score but very little
eosinophilic airway inﬂammation. Groups C and D both had
a discordant asthma control score and eosinophilic inﬂamma-
tion, with Group C predominantly having a high asthma control
score and Group D predominantly having eosinophilic airway
inﬂammation. The clinical characteristics of the 99 subjects in
this study were not signiﬁcantly different from those of the
remaining 74 subjects with severe asthma who underwent
HRCT scanning but were not included (data not shown).
The mean (SEM) LA/BSA (mm
2/m
2) of RB1 was signiﬁcantly
smaller in all severe asthma subphenotypes than in the control
group (table 2 and ﬁgure 1) while the mean (SEM) RB1 %WA
was signiﬁcantly increased in all severe asthma subphenotypes
compared with the control group (table 2 and ﬁgure 2). There
was no difference in wall area between subphenotypes. RB10
results were similar to those of RB1 (see online supplement).
Univariate and multiple regression analysis to explore structure
and function relationship in severe asthma
Univariate analysis of the relationship between RB1 dimensions
and clinical indices is shown in table 3 and ﬁgures 3 and 4. RB1
%WA correlated signiﬁcantly with disease duration, post-bron-
chodilator FEV1% predicted, post-bronchodilator FEV1/FVC,
Table 1 Clinical and sputum characteristics of patient groups and clinical characteristics of control subjects
Group A (n[20) Group B (n[16) Group C (n[25) Group D (n[38) Control (n[16)
Clinical characteristics
Age (years) 52 (3) 43 (3) 51 (3) 51 (2) 54 (4)
Gender (M:F) 6:14 3:13 11:14 20:18 9:7
BMI (kg/m
2) 29 (1) 38 (1)* 26 (1) 28 (1) 27 (2)
Age of onset (years) 24 (3) 20 (4) 28 (4) 31 (4)
Disease duration (years) 28 (4) 23 (4) 24 (4) 20 (3)
Smoking status (%) Never 58 56 71 46 56
Ex 26 38 21 41 44
Current 16 6 8 13 0
Atopy (%) 45 75 48 71
Severe exacerbations/year 3.1 (0.7) 3.6 (0.9) 1.4 (0.5) 2.1 (0.4)
JACS 2.9 (0.2) 2.8 (0.2) 2.6 (0.2) 1.7 (0.1)*
Prebronchodilator FEV1 (% predicted) 64 (5) 75 (6) 75 (6) 76 (4)
Prebronchodilator FEV1/FVC 67 (3) 74 (3) 69 (3) 68 (3)
Postbronchodilator FEV1 (% predicted) 74 (5) 81 (7) 81 (5) 80 (4) 106 (4)*
Postbronchodilator FEV1/FVC 66 (3) 77 (2) 70 (3) 70 (2) 78 (2)y
Bronchodilator response (%) 25 (3)* 10 (2) 6 (2) 3 (2)
Inhaled CS (%) 100 100 100 100
Inhaled CS dose BDP (mg/24 h) 2066 (220) 1943 (301) 2071 (218) 1761 (145)
LABA (%) 100 100 100 100
Oral prednisolone use (% of subjects) 50 36 44 42
Oral prednisolone dose (mg) 12.8 (1.5) 10.8 (2.4) 10.3 (2.0) 8.1 (0.8)
Sputum characteristics
Eosinophils (%) 3.9 (1.8e13.7) 0.3 (0.3e1.3) 0.3 (0.3e0.4) 6.6 (2.7e14.2)z
Eosinophils AUC (%) 4.7 (3.6e11.7) 0.9 (0.2e1.5) 1.2 (0.3e6.7) 9.4 (1.2e16.1)x
Neutrophils (%) 77 (48e87) 83 (27e90) 84 (43e93) 56 (30e78)
Neutrophils AUC (%) 71 (60e82) 69 (56e79) 63 (51e81) 61 (50e75)
Data expressed as mean (SEM) or median (IQR).
BDP equivalents: ﬂuticasone 2:1, budesonide 1.25:1, mometasone 1.25:1, QVAR 2:1, ciclesonide 2.5:1.
Intergroup comparison: parametric data, one-way ANOVA with Tukey test to compare all pairs of columns *p<0.05, yp<0.05 control vs group A; non-parametric data, KruskaleWallis test
with Dunn’s multiple comparison test to compare all pairs of columns, zp<0.05, xp<0.05 group D vs group B.
Group A, patients with severe asthma with a concordant asthma control score and eosinophilic inﬂammation with a signiﬁcantly greater bronchodilator response; group B, patients with severe
asthma who were predominantly women with high body mass index and evidence of a high asthma control score but very little eosinophilic airway inﬂammation; group C, patients with severe
asthma with a predominantly high asthma control score and very little eosinophilic airway inﬂammation; group D, patients with severe asthma with predominantly eosinophilic airway
inﬂammation and signiﬁcantly low asthma control score.
AUC, area under the time curve; BDP, beclometasone dipropionate; BMI, body mass index; CS, corticosteroid; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; JACS, Juniper
Asthma Control Score; LABA, long-acting b agonist.
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AsthmaJuniper Asthma Control Score (JACS) and sputum neutrophil
AUC (%). Standard multiple regression was performed using the
‘Enter’ method between RB1 %WA as the dependent variable
and disease duration, post-bronchodilator FEV1% predicted,
sputum neutrophil AUC and modiﬁed JACS (6-point score
without FEV1% predicted)
20 as the independent variables,
selected based on the univariate analysis. With the use of
ap <0.001 criterion for Mahalanobis distance, no outliers among
the cases were found. No multicollinearity or singularity
was detected. Normality, linearity, homoscedasticity and
independence of residuals were conﬁrmed. Table 4 shows the
unstandardised correlation coefﬁcients (B), the standardised
correlation coefﬁcient (b), the semipartial correlations R
2 and
adjusted R
2.
Post-bronchodilator FEV1% predicted and sputum neutrophil
AUC (%) made a statistically signiﬁcant contribution to the
regression model for prediction of RB1 %WA, with the former
making the strongest unique contribution to explaining the
dependent variable as indicated by standardised coefﬁcients.
DISCUSSION
We found that, in patients with severe asthma, RB1da proximal
third-generation airwaydwas remodelled with luminal
narrowing and increased %WA. The degree of airway remodel-
ling was similar across clinical subphenotypes determined by
cluster analysis and was independent of smoking status.
Importantly, we conﬁrmed that %WA was associated with lung
function impairment and was signiﬁcantly greater in patients
with severe asthma with persistent airﬂow obstruction than in
those without. For the ﬁrst time we have shown that %WA is
associated with the burden of neutrophilic airway inﬂammation
over time, suggesting that this component of the airway
inﬂammatory proﬁle may be important in airway remodelling.
Table 2 Dimensions of right upper lobe apical segmental bronchus (RB1) in patient groups and control subjects
Group A (n[20) Group B (n[16) Group C (n[25) Group D (n[38) Controls (n[16) p Value
Wall area (%) 70.9 (1.6) 70.4 (1.6) 69.9 (1.4) 70.3 (1.1) 63.7 (1.0) 0.009
Wall area/BSA (mm
2/m
2) 12.5 (0.9) 11.1 (1.3) 13.1 (0.8) 12.1 (0.6) 13.9 (1.1) 0.35
Lumen area/BSA (mm
2/m
2) 5.4 (0.6) 4.7 (0.6) 5.7 (0.5) 5.4 (0.4) 7.9 (0.5) 0.008
Total area/BSA (mm
2/m
2) 17.9 (1.4) 15.9 (1.8) 18.8 (1.2) 17.5 (1.0) 21.8 (1.5) 0.10
Data expressed as mean (SEM).
Intergroup comparisons: one-way ANOVA with Tukey test to compare all pairs of columns.
Group A, patients with severe asthma with a concordant asthma control score and eosinophilic inﬂammation with a signiﬁcantly greater bronchodilator response; group B, patients with severe
asthma who were predominantly women with high body mass index and evidence of a high asthma control score but very little eosinophilic airway inﬂammation; group C, patients with severe
asthma with a predominantly high asthma control score and very little eosinophilic airway inﬂammation; group D, patients with severe asthma with predominantly eosinophilic airway
inﬂammation and signiﬁcantly low asthma control score.
BSA, body surface area.
Figure 1 Comparison of right upper lobe apical segmental bronchus
(RB1) lumen area/body surface area (LA/BSA, mm
2/m
2) of four severe
asthma phenotypes and control subjects (p¼0.008, ANOVA; *p<0.05,
Tukey test to compare all pairs of columns). Group A, patients with
severe asthma with a concordant asthma control score and eosinophilic
inﬂammation with a signiﬁcantly greater bronchodilator response; group
B, patients with severe asthma who were predominantly women with
high body mass index and evidence of a high asthma control score but
very little eosinophilic airway inﬂammation; group C, patients with
severe asthma with a predominantly high asthma control score and very
little eosinophilic airway inﬂammation; group D, patients with severe
asthma with predominantly eosinophilic airway inﬂammation and
signiﬁcantly low asthma control score.
Figure 2 Comparison of right upper lobe apical segmental bronchus
(RB1) percentage wall area (%WA) of four severe asthma phenotypes
and control subjects (p¼0.009, ANOVA; *p<0.05, Tukey test to
compare all pairs of columns). Group A, patients with severe asthma
with a concordant asthma control score and eosinophilic inﬂammation
with a signiﬁcantly greater bronchodilator response; group B, patients
with severe asthma who were predominantly women with high body
mass index and evidence of a high asthma control score but very little
eosinophilic airway inﬂammation; group C, patients with severe asthma
with a predominantly high asthma control score and very little
eosinophilic airway inﬂammation; group D, patients with severe asthma
with predominantly eosinophilic airway inﬂammation and signiﬁcantly
low asthma control score.
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AsthmaAirway remodelling is an established feature of asthma,
particularly in those with severe disease. Our ﬁndings conﬁrm
that airway wall thickening and reduced luminal patency are
features of severe asthma. This altered geometry in patients
with severe asthma compared with healthy controls may be
important in determining physiological characteristics such as
airway hyper-responsiveness and airﬂow obstruction. However,
there is increasing recognition that severe asthma is a hetero-
geneous condition and the relationship between clinical, physi-
ological and inﬂammatory features of disease and remodelling is
poorly understood.
Whether subjects with airway remodelling represent a distinct
asthma subphenotype is unknown. Cluster analysis has been
applied to determine asthma subphenotypes.
10 21 Using
a combination of factor and cluster analysis, we have previously
reported four novel subphenotypes in severe asthma.
10 Here we
used the same approach to categorise our patients with severe
asthma into distinct groups. The four subphenotypes identiﬁed
had very similar characteristics to our earlier report. Impor-
tantly, airway remodelling was a feature of all four subpheno-
types and there were no differences between them.
Bronchoconstriction may cause airway luminal narrowing
without change in wall area.
22 We are conﬁdent that the RB1
luminal narrowing in the subjects with severe asthma in this
study does not simply reﬂect reversible bronchoconstriction as
a consequence of airway smooth muscle shortening, as all
subjects in our study were on long-acting b agonists and these
were not withheld before undertaking the CT scan.
In addition to this unbiased approach to phenotyping, we
prespeciﬁed criteria to stratify our subjects into those with or
without persistent airﬂow obstruction, smoking status and the
presence or absence of sputum eosinophilia. Those with persis-
tent airﬂow limitation had the most marked CT evidence of
remodelling whereas altered airway geometry was independent
of smoking status. Our observation that RB1 %WA was asso-
ciated with the post-bronchodilator FEV1% predicted is in
keeping with previous reports in asthma
5 6 and chronic
obstructive pulmonary disease.
23 In addition, we have previ-
ously identiﬁed that, in asthma, RB1 %WA is associated with
airway hyper-responsiveness.
8 Taken together, these ﬁndings
support the view that the changes in airway geometry are
functionally important.
To date there has been a paucity of studies exploring the
associations between remodelling assessed by CT and airway
inﬂammation. Sputum analysis provides a non-invasive safe tool
to assess airway inﬂammation and has been widely applied in
the study of severe asthma. Indeed, the identiﬁcation of eosin-
ophilic airway inﬂammation in severe asthma has evolved as
a powerful diagnostic tool to predict the response to cortico-
steroids
24 and to prevent exacerbations.
11 12 In addition to
eosinophilic airway inﬂammation, the existence of a distinct
subgroup with neutrophilic airway inﬂammation in severe
25 as
well as mild-to-moderate
26 asthma is well recognised. Both
eosinophilic
27 28 and neutrophilic
29 inﬂammation have been
implicated in the development of persistent airﬂow obstruction.
ten Brinke et al
28 showed that the only independent factor
associated with persistent airﬂow limitation was a differential
sputum eosinophilia whereas we
29 and others
30 demonstrated
that raised differential sputum eosinophil and neutrophil counts
were both associated with a lower prebronchodilator FEV1. Here
we report for the ﬁrst time that the RB1 %WA is increased in
subjects with and without eosinophilic inﬂammation and is
associated with the preceding burden of neutrophilic inﬂam-
mation over time measured by repeated sputum analysis. Our
observation that airway wall thickening in severe asthma can be
present in both eosinophilic and non-eosinophilic asthma but is
Table 3 Univariate analysis of relationship between RB1 dimensions
and clinical indices
LA/BSA
(mm
2/m
2)
WA/BSA
(mm
2/m
2)
TA/BSA
(mm
2/m
2) %WA
Disease duration (years)  0.16  0.003  0.08 0.21*
Postbronchodilator FEV1 (% predicted) 0.24*  0.006 0.09  0.41z
Postbronchodilator FEV1/FVC 0.22* 0.17 0.20*  0.23*
JACS  0.03 0.12 0.07 0.23*
Sputum eosinophils (%) 0.10 0.01 0.05  0.08
Sputum eosinophils AUC (%) 0.16 0.02 0.08  0.16
Sputum neutrophils (%)  0.09 0.04  0.01 0.12
Sputum neutrophils AUC (%)  0.31*  0.08  0.18 0.36y
Data expressed as Pearson correlation coefﬁcient.
n¼99 for all variables except for sputum eosinophils AUC (%) and sputum neutrophils AUC
(%), n¼91.
*p<0.05.
yp<0.005.
zp<0.001.
AUC, area under the curve per unit time; BSA, body surface area; FEV1, forced expiratory
volume in 1 s, FVC, forced vital capacity; JACS, Juniper Asthma Control Score; LA, lumen
area; TA, total area; WA, wall area.
Figure 3 Correlation between right upper lobe apical segmental
bronchus (RB1) percentage wall area (%WA) and postbronchodilator
(postBD) forced expiratory volume in 1 s (FEV1)% predicted in patients
with severe asthma (r¼0.41, p<0.0001).
Figure 4 Correlation between right upper lobe apical segmental
bronchus (RB1) percentage wall area (%WA) and sputum neutrophil area
under the curve (AUC, %) in patients with severe asthma (r¼0.36,
p<0.005).
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Asthmanot related to the degree of airway inﬂammation measured
cross-sectionally is in keeping with other imaging studies in
mild-to-moderate disease. Little et al failed to ﬁnd an association
between airway wall geometry and sputum neutrophils or
exhaled nitric oxide.
31 Similarly, Niimi et al failed to ﬁnd an
association between serum eosinophil cationic protein and
airway wall geometry.
5 These studies were cross-sectional in
design and did not capture the temporal relationship between
inﬂammation and remodelling. Our study ﬁndings supporting
a role for persistent neutrophilic inﬂammation in the develop-
ment of airway remodelling is in contrast to our recent report
7
that the RB1 wall area decreased after 1 year of treatment with
anti-IL-5 compared with placebo, providing strong evidence in
favour of a key role for eosinophils in airway remodelling
determined by CT. One possible explanation for this apparent
paradox is that eosinophilic and neutrophilic inﬂammation may
both contribute to airway remodelling but they may exert
different effects on airway geometry and lung function. In this
report the changes in RB1 %WA are largely driven by luminal
narrowing which may be more closely related to neutrophilic
inﬂammation whereas, in our study of anti-IL-5,
7 the wall area
was decreased without affecting the luminal area. Importantly,
the change in wall area in response to anti-IL-5 was small but
signiﬁcant, suggesting that additional components of airway
inﬂammation play a role in remodelling. This view is supported
by the association of other markers of airway inﬂammation in
sputum such as transforming growth factor b
32 and the ratio of
matrix metalloproteinase-9 to tissue inhibitor of metallo-
proteinases-1
33 and airway wall thickening.
This recognition of the complexity of the interactions of
different aspects of the airway inﬂammation underlying asthma
and their temporal course provides an explanation for the
apparent discrepancy between some CTstudies. Methodological
variations or difﬁculties in the measurement of airway dimen-
sions and the inability of CT scanning to dissect out various
individual components of airway remodelling may also
contribute to the apparent discrepancy between CTstudies. This
highlights the need for further prospective interventional and
longitudinal studies.
In addition to FEV1% predicted andneutrophilic inﬂammation,
our univariate analysis also showed that disease duration was
associated with thickening of the airway wall in severe asthma.
This is in keeping with previous reports which have shown that
vascular remodelling of the airway wall is related to disease
duration
34andthatdurationofdiseaseisassociatedwithincreased
airway smooth muscle mass and luminal narrowing in patients
with fatal asthma.
35 However, this feature and the univariate
association between asthma control and %WAwere not found to
be independent predictors in the multiple regression model.
Our study has a number of potential limitations. The HRCT
scan was part of the clinical assessment of the subjects, was not
undertaken in all subjects and in some subjects the CTscan did
not adequately capture the RB1 so these subjects were excluded.
We are conﬁdent that our ﬁndings can be extended to those
subjects who underwent CT scanning but were excluded as
there were no differences in the clinical characteristics between
these groups. However, our ﬁndings cannot be simply extrapo-
lated to our severe asthma population as a whole as we have
previously reported that subjects in our ‘difﬁcult asthma’ clinic
who undergo HRCT scanning are older, have longer disease
duration, poorer lung function, are treated with a higher dose of
inhaled corticosteroids and oral corticosteroids and have
increased neutrophilic airway inﬂammation.
4 There is therefore
a need to undertake multicentre prospective studies that include
the full spectrum of patients with severe asthma. In addition,
we analysed the images of RB1 from standard HRCTscans and
not from narrow collimation CTscans which capture RB1 across
its entire length. We found that the variability in RB1 dimen-
sions across its length was small and considerably less than the
between-subject variability. This was therefore unlikely to have
an impact on our ﬁndings. Our analysis was limited to third-
generation bronchial airways, unlike other studies
36 where
differences between subjects with asthma and controls were
only found in airways of higher generations. We and others have
established that the measurement of RB1 is closely associated
with the measurement of multiple airways.
68RB10 dimensions
were correlated with those of RB1 and, importantly, the degree
of RB10 remodelling in patients with severe asthma and control
subjects reﬂected remodelling changes observed in RB1
suggesting that, despite disease heterogeneity, RB1 dimensions
serve as a good surrogate for airway wall remodelling in this
disease cohort as previously described. The FWHM technique
used for quantitative assessment in this study is known to cause
errors in airway wall estimation due to CTscanner point spread
function. To overcome such problems, various other techniques
such as the ‘laplacian of Gaussian algorithm’
36 which uses
smoothing and edge detection ﬁlters to segment airways, the
‘maximum-likelihood method’
37 whereby the attenuation
threshold along each ray is matched to an ideal calculated ray
and the ‘energy driven contour estimation method’
38 which
incorporates shape independent quantiﬁcation have been devel-
oped. Most of the newer software platforms are designed to
work on volumetric CT scans and not the standard sequential
HRCT scans. We used an airway phantom model with gold
standard measures obtained using high-precision micro-CT as
previously described
78to correct potential size and oblique
orientation-related errors in quantiﬁcation of airway dimen-
sions. Moreover, we have measured and compared the
Table 4 Standard multiple regression
Independent variables
Unstandardised
coefﬁcients B (SE) 95% CI
Standardised
coefﬁcients b
Semipartial
correlations p Value
Postbronchodilator FEV1 (% predicted)  0.09 (0.03)  0.16 to  0.02  0.32  0.28 0.008
Sputum neutrophils AUC (%) 0.12 (0.05) 0.01 to 0.22 0.26 0.28 0.03
Disease duration (years) 0.02 (0.04)  0.07 to 0.10 0.05 0.04 0.70
Modiﬁed JACS 0.55 (0.69)  0.82 to 1.92 0.09 0.09 0.42
Dependent variable is RB1 %WA (n¼91).
Model R
2¼0.27*, adjusted R
2¼0.23, R¼0.52, p¼0.001.
*Unique variance¼0.16; shared variance¼0.11.
Model equation: RB1 %WA ¼66.02e0.09 (postbronchodialator FEV1% predicted) +0.12 (sputum neutrophils AUC(%)).
Standard multiple regression using ‘enter’ method.
Unstandardised coefﬁcients are used to construct a regression equation. Standardised coefﬁcients are used to compare the unique contribution of each independent variable. Semipartial
correlation coefﬁcient squared indicates the contribution of the independent variable to the total R
2.
AUC, area under the curve per unit time; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; JACS, Juniper Asthma Control Score; RB1, right upper lobe apical segmental
bronchus; WA, wall area.
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Asthmathird-generation proximal airway in all subjects. We are there-
fore conﬁdent that the potential errors associated with the
FWHM technique are unlikely to affect our results.
In conclusion, the degree of airway wall remodelling assessed
by CTscanning was similar in all severe asthma subphenotypes
and was associated with airﬂow limitation and neutrophilic
inﬂammation. Longitudinal studies are required in severe asthma
to assess the natural history of remodelling, its association with
airway inﬂammation and function and its response to current
and novel therapies.
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